0000000000862301
AUTHOR
A Pucci
PRIMI DATI SUGLI INNESTI DI ABIES NEBRODENSIS (LOJAC.) MATTEI ESEGUITI SU ABETI ESOTICI NELL’AREA DI INDIGENATO (MADONIE)
C2 = PRIMI DATI SUGLI INNESTI DI ABIES NEBRODENSIS (LOJAC.) MATTEI ESEGUITI SU ABETI ESOTICI NELL’AREA DI INDIGENATO (MADONIE) R. SCHICCHI, P. BONOMO, M. CANDORE, G. DI NOTO, A. PUCCI, F. TRAPANI, P. MARINO Dipartimento di Biologia Ambientale e Biodiversità dell'Università, via Archirafi 38, 90123 Palermo (I) rosario.schicchi@unipa.it Abies nebrodensis è una specie endemica relitta, gravemente minacciata di estinzione, la cui popolazione naturale è costituita da 30 individui distribuiti discontinuamente in una piccola area del territorio di Polizzi Generosa, all’interno del Parco naturale delle Madonie in Sicilia. La minaccia di estinzione è dovuta, oltre all'esiguità della popolazione, al …
Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity
Background Randomized controlled trials (RCTs) in the field of diabetes have limitations inherent to the fact that design, setting, and patient characteristics may be poorly transferrable to clinical practice. Thus, evidence from studies using routinely accumulated clinical data are increasingly valued. Aims We herein describe rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes), a multicenter retrospective nationwide study conducted at 50 specialist outpatient clinics in Italy and promoted by the Italian Diabetes Society. Data synthesis The primary objective of the study is to describe the baseline clinical characteristics (particularly HbA1c) of pa…
Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study
Introduction DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice. Methods This was a multicenter retrospective study on diabetes outpatient clinics comparing the effectiveness of DPP4i versus gliclazide extended release. The primary endpoint was change from baseline in HbA1c. Secondary endpoints were changes in fasting plasma glucose, body weight, and systolic blood pressure. Automated software extracted data from the same clinical electronic chart system at all centers. Propensity score matching (PSM) was used to generate comparable coh…